​

IN8bio (INAB) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

INAB Stock Rating

IN8bio stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (75.00%), 1 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 1 3 Strong Sell Sell Hold Buy Strong Buy

INAB Price Target Upside V Benchmarks

TypeNameUpside
StockIN8bio-
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$2.38$2.38$2.38
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2522---4
May, 2512---3
Apr, 2512---3
Mar, 2522---4
Feb, 25211--4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 03, 2024LaidlawBuyBuyhold
Aug 30, 2022H.C. WainwrightBuyinitialise

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.00$-0.57----
Avg Forecast$-0.90$-0.56$-0.28$-0.31$-0.25$-0.05
High Forecast$-0.90$-0.53$-0.23$-0.17$-0.15$-0.05
Low Forecast$-0.90$-0.59$-0.31$-0.69$-0.43$-0.05
Surprise %11.11%1.79%----

Revenue Forecast

$0 $10M $20M $30M $40M $50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$9.20M$47.67M$2.67M$22.74M
High Forecast--$9.20M$47.67M$2.67M$22.74M
Low Forecast--$9.20M$47.67M$2.67M$22.74M
Surprise %------

Net Income Forecast

$-35M $-28M $-21M $-14M $-7M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-30.01M$-30.44M----
Avg Forecast$-26.98M$-16.82M$-8.03M$-12.92M$-8.64M$-1.42M
High Forecast$-26.98M$-15.92M$-6.78M$-5.17M$-4.39M$-1.42M
Low Forecast$-26.98M$-17.73M$-9.28M$-20.67M$-12.90M$-1.42M
Surprise %11.23%80.92%----

INAB Forecast FAQ

Is IN8bio stock a buy?

IN8bio stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that IN8bio is a favorable investment for most analysts.

What is IN8bio's price target?

IN8bio's price target, set by 4 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $2.38.

How does IN8bio stock forecast compare to its benchmarks?

IN8bio's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (23.68%) and underperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for IN8bio over the past three months?

  • June 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is IN8bio’s EPS forecast?

IN8bio's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.28, marking a -50.88% decrease from the reported $-0.57 in 2024. Estimates for the following years are $-0.31 in 2026, $-0.25 in 2027, and $-0.05 in 2028.

What is IN8bio’s revenue forecast?

IN8bio's average annual revenue forecast for its fiscal year ending in December 2025 is $9.2M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $47.67M, followed by $2.67M for 2027, and $22.74M for 2028.

What is IN8bio’s net income forecast?

IN8bio's net income forecast for the fiscal year ending in December 2025 stands at $-8.034M, representing a -73.60% decrease from the reported $-30.437M in 2024. Projections indicate $-12.921M in 2026, $-8.643M in 2027, and $-1.419M in 2028.